Temporary Rise in Blood Thrombogenicity in Patients with Acute Myocardial Infarction

Author:

Kosugi Shumpei1ORCID,Ueda Yasunori1ORCID,Abe Haruhiko1,Ikeoka Kuniyasu1,Mishima Tsuyoshi1,Ozaki Tatsuhisa1,Takayasu Kohtaro1,Ohashi Takuya1,Yamane Haruya1,Nakamura Masayuki1,Fukushima Takashi1,Horiuchi Kohei1,Iehara Takashi1,Osaki Satoshi1,Ozato Kazuki1,Inoue Koichi1,Koretsune Yukihiro1,Matsumura Yasushi1

Affiliation:

1. Cardiovascular Division, National Hospital Organization Osaka National Hospital, Osaka, Japan

Abstract

Abstract Objective Although blood thrombogenicity seems to be one of the determinant factors for the development of acute myocardial infarction (MI), it has not been dealt with in-depth. This study aimed to investigate blood thrombogenicity and its change in acute MI patients. Methods and Results We designed a prospective, observational study that included 51 acute MI patients and 83 stable coronary artery disease (CAD) patients who underwent cardiac catheterization, comparing thrombogenicity of the whole blood between: (1) acute MI patients and stable CAD patients; and (2) acute and chronic phase in MI patients. Blood thrombogenicity was evaluated by the Total Thrombus-Formation Analysis System (T-TAS) using the area under the flow pressure curve (AUC30) for the AR-chip. Acute MI patients had significantly higher AUC30 than stable CAD patients (median [interquartile range], 1,771 [1,585–1,884] vs. 1,677 [1,527–1,756], p = 0.010). Multivariate regression analysis identified acute MI with initial TIMI flow grade 0/1 as an independent determinant of high AUC30 (β = 0.211, p = 0.013). In acute MI patients, AUC30 decreased significantly from acute to chronic phase (1,859 [1,550–2,008] to 1,521 [1,328–1,745], p = 0.001). Conclusion Blood thrombogenicity was significantly higher in acute MI patients than in stable CAD patients. Acute MI with initial TIMI flow grade 0/1 was significantly associated with high blood thrombogenicity by multivariate analysis. In acute MI patients, blood thrombogenicity was temporarily higher in acute phase than in chronic phase.

Funder

Nihon Kohden

Daiichi-Sankyo

Bayer HealthCare

Astellas Pharma

Shionogi

Pfizer Japan

Abbott Japan

Teijin Pharma

Publisher

Georg Thieme Verlag KG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3